文献速递癫痫神经免疫

静脉免疫球蛋白治疗LGI1/CASPR2抗体相关癫痫的随机安慰剂对照试验

Randomized Placebo-Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy.
PubMed 文献 · Ann Neurol · 2019-12-14

这项随机双盲安慰剂对照试验评估静脉免疫球蛋白(IVIG)减少LGI1/CASPR2-IgG血清阳性成人患者癫痫发作频率的疗效,计划入组30例但仅入组17例后因入组缓慢终止。IVIG组8例中6例应答,安慰剂组9例中2例应答(p=0.044,OR=10.5,95%CI 1.1-98.9)。

要点

  • IVIG组8例中6例发作频率较基线减少≥50%,安慰剂组9例中2例(p=0.044)。
  • LGI1-IgG亚组中IVIG组8例中6例应答,安慰剂组6例中0例应答。
  • 研究因入组缓慢提前终止,未达原定样本量,结论需谨慎解读。

核心结论

  • IVIG在减少LGI1/CASPR2-IgG血清阳性患者癫痫发作频率方面优于安慰剂,主要终点达统计学显著。
  • LGI1-IgG亚组同样显示IVIG优于安慰剂,但研究未达原定样本量,需谨慎解读。

研究设计与样本

  • 随机双盲安慰剂对照试验,计划入组30例每周发作≥2次的LGI1/CASPR2-IgG血清阳性成人患者。
  • 实际入组17例(LGI1-IgG 14例,CASPR2-IgG 3例),34个月后因入组缓慢终止。
  • IVIG方案为第1天0.5g/kg、第2天1g/kg、第3和第5周0.6g/kg,对照为等体积生理盐水。
  • 盲法阶段后,安慰剂组无应答者接受IVIG开放标签治疗。
  • 主要临床结局为基线至第5周癫痫发作频率减少50%。

主要发现

  • IVIG组8例中6例为应答者,安慰剂组9例中2例(p=0.044,OR=10.5,95%CI 1.1-98.9)。
  • LGI1-IgG亚组中IVIG组8例中6例应答,安慰剂组6例中0例应答。
  • 盲法阶段结束时,IVIG组2例LGI1-IgG血清阳性患者无发作,安慰剂组0例。
  • 进入开放标签IVIG组的6例中4例报告发作频率减少≥50%。
  • 未发现与LGI1/CASPR2-IgG1-4亚类相关。

关键数值与推荐

  • 主要终点应答定义为癫痫发作频率较基线减少≥50%(基线至第5周)。
  • 入组标准为LGI1/CASPR2-IgG血清阳性成人且每周发作≥2次。

临床怎么用

  • 对于LGI1/CASPR2-IgG血清阳性且发作频繁的成人患者,IVIG可考虑用于减少癫痫发作频率。
  • LGI1-IgG亚组可能从IVIG获益更明显,但需结合样本量有限的局限。
  • IVIG方案为第1天0.5g/kg、第2天1g/kg、第3和第5周0.6g/kg。

局限性

  • 研究因入组缓慢提前终止,未达原定30例样本量。
  • 实际样本量小(17例),CASPR2-IgG亚组仅3例。
  • 结果需在未达原定样本量的前提下谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Drug-resistant seizures are common in patients with leucine-rich, glioma-inactivated 1 (LGI1)-IgG associated and contactin-associated protein-like 2 (CASPR2)-IgG associated encephalitis. We performed the first randomized double-blind placebo-controlled trial to evaluate efficacy of intravenous immunoglobulin (IVIG) in reducing seizure frequency. METHODS: Our enrollment goal was 30 LGI1/CASPR2-IgG-seropositive adult patients with ≥2 seizures per week. Patients were randomized to receive IVIG (0.5g/kg day 1, 1g/kg day 2, 0.6g/kg weeks 3 and 5) or volume-matched intravenous normal saline. Following the blinded phase, the nonresponders in the placebo group received IVIG. The primary clinical outcome was 50% reduction in seizure frequency from baseline to 5 weeks. RESULTS: After enrollment of 17 patients (LGI1-IgG, 14; CASPR2-IgG, 3) over 34 months, the study was terminated due to slow enrollment. Six of 8 patients in the IVIG group were responders, compared to 2 of 9 in the placebo group (p = 0.044, odds ratio = 10.5, 95% confidence interval = 1.1-98.9). For the LGI1-IgG seropositive subgroup, 6 of 8 patients in the IVIG group were responders, compared to zero of 6 in the placebo group. Two LGI1-IgG-seropositive patients receiving IVIG, but none receiving placebo, were seizure-free at the end of the blinded phase. Four of the 6 patients entering the open-label IVIG arm reported ≥50% reduction in seizure frequency. There were no correlations with LGI1/CASPR2-IgG1-4 subclasses. INTERPRETATION: Superiority of IVIG to placebo reached statistical significance for the primary endpoint for all patients and the subset with LGI1-IgG. These results have to be interpreted with the caveat that the study did not reach its originally selected sample size. ANN NEUROL 2020;87:313-323.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Dubey D, Britton J, McKeon A, et al. Randomized Placebo-Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy. Ann Neurol. 2019. PMID: 31782181. doi:10.1002/ana.25655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。